CORT Corcept Therapeutics Incorporat

9.27
+0  (1%)
Previous Close 9.20
Open 9.25
Price To book 25.07
Market Cap 1.05B
Shares 112,942,000
Volume 893,893
Short Ratio 6.14
Av. Daily Volume 899,642

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 2 ongoing.
Mifepristone plus Abraxane
Triple-negative breast cancer
Phase 2 ongoing.
Mifepristone plus enzalutamide
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data released December 10, 2016 - 4/21 partial responses.
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 2 initiated 1Q 2016. Enrolling as of January 2017.
CORT125134
Solid tumors - cancer
Phase 2 trial initiated 2Q 2016. Data due by the end of 2017.
CORT125134
Cushing’s syndrome

Latest News

  1. Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : April 25, 2017
  2. Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
  3. Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April 24, 2017
  4. Here's Why Corecept Therapeutics Incorporated Had a Rough Day
  5. Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
  6. Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?
  7. Corcept (CORT) Strives to Commercialize Key Drug Korlym
  8. Corcept Therapeutices Eyes Another Double
  9. Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics
  10. Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging'
  11. Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  12. Corcept beats 4Q profit forecasts
  13. Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance
  14. Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : February 14, 2017
  15. Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT
  16. Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance
  17. Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
  18. Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : January 11, 2017
  19. 3 Stocks Expected to More Than Double Their Earnings in 2017
  20. Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : December 23, 2016